Article

Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and Organoids

2023-12-20

Abstract excerpt

HER2 ( ERBB2 ) is a major therapeutic drug target in breast cancer and The Cancer Genome Atlas (TCGA) Breast Cancer project and other studies have identified HER2 activating mutations in breast cancers without HER2 gene amplification. HER2 activating mutations occur in 2-5% of metastatic breast cancer patients (MBC), and clinical trials have shown that the irreversible pan-HER tyrosine kinase inhibitor, neratinib...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 3286e51d-e1bd-5af5-922f-561a87f1244f
DOI: 10.1101/2023.12.19.572069

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Neratinib Synergizes with Trastuzumab Antibody Drug Conjugate or with Vinorelbine to Treat HER2 Mutated Breast Cancer Patient Derived Xenografts and OrganoidsDOI 10.1101/2023.12.19.572069Read

Use of Ex Vivo Patient-Derived Tumor Organotypic Spheroids to Identify Combination Therapies for HER2 Mutant Non-Small Cell Lung Cancer.Semantic proximity Read

Breast cancer mutations HER2 <sup>V777L</sup> and PIK3CA <sup>H1047R</sup> activate the p21-CDK4/6 –Cyclin D1 axis driving tumorigenesis and drug resistanceSemantic proximity Read

Breast Cancer Mutations HER2V777L and PIK3CAH1047R Activate the p21-CDK4/6-Cyclin D1 Axis to Drive Tumorigenesis and Drug Resistance.Semantic proximity Read

Patient-derived tumor organoids from resected non-small cell lung cancers for high-throughput response testing with approved and repurposed drugsSemantic proximity Read

A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacologySemantic proximity Read

Establishing conditions for the generation and maintenance of estrogen receptor-positive organoid models of breast cancerSemantic proximity Read

Personalized treatment of HER2-positive lung adenocarcinoma using Human Organoid Drug Sensitivity Test.Semantic proximity Read

Organoids from Patient Biopsy Samples can Predict the Response of BC Patients to Neoadjuvant ChemotherapySemantic proximity Read

Patient-derived renal cell carcinoma organoids for precision medicineSemantic proximity Read

HER2 exon 20 insertions in non-small-cell lung cancer are sensitive to the irreversible pan-HER receptor tyrosine kinase inhibitor pyrotinib.Semantic proximity Read